Exact Sciences (STU:EXK) 3-Year Revenue Growth Rate : 12.00% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences 3-Year Revenue Growth Rate?

Exact Sciences's Revenue per Share for the three months ended in Mar. 2024 was €3.22.

During the past 12 months, Exact Sciences's average Revenue per Share Growth Rate was 12.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 12.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 26.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 84.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Exact Sciences was 371.00% per year. The lowest was -34.70% per year. And the median was 30.75% per year.

Competitive Comparison of Exact Sciences's 3-Year Revenue Growth Rate

For the Diagnostics & Research subindustry, Exact Sciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Sciences's 3-Year Revenue Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Exact Sciences's 3-Year Revenue Growth Rate falls into.

Exact Sciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Exact Sciences (STU:EXK) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Exact Sciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Exact Sciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Sciences (STU:EXK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

EXAS:USA

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.